OTCMKTS:PHGUF

Pharming Group Q3 2025 Earnings Results & Report

Pharming Group logo
$1.26 0.00 (0.00%)
As of 11/13/2026

Pharming Group beat analyst expectations on both earnings and revenue in its Q3 2025 results, released November 6, 2025. The company reported EPS of $0.01 versus the $0.0005 consensus estimate, while revenue of $97.30 million topped the $80.18 million estimate by $17.12 million.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens

Pharming Group EPS Results

Actual EPS
$0.01
Consensus EPS
$0.0005
Beat/Miss
Beat by +$0.0096
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 5 quarters

Pharming Group Revenue Results

Actual Revenue
$97.30 million
Expected Revenue
$80.18 million
Beat/Miss
Beat by +$17.12 million
YoY Revenue Growth
N/A

Conference Call Resources

Pharming Group Q3 2025 Earnings FAQ

Pharming Group (OTCMKTS:PHGUF) reported earnings of $0.01 per share for Q3 2025, beating the consensus estimate of $0.0005. The report was announced on Thursday, November 6, 2025.

Pharming Group reported revenue of $97.30 million for Q3 2025, against a consensus estimate of $80.18 million.

Pharming Group Earnings Headlines

Your Copy is on Hold (Claim it now)
James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.tc pixel
See More Pharming Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pharming Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharming Group and other key companies, straight to your email.

About Pharming Group

Pharming Group (OTCMKTS:PHGUF) is a biotechnology company based in Leiden, the Netherlands, focused on developing and commercializing medicines for rare diseases. Its portfolio includes treatments for hereditary angioedema and activated phosphoinositide 3-kinase delta syndrome (APDS).

The company’s products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute hereditary angioedema attacks, and Joenja (leniolisib), an oral treatment for APDS. Pharming developed Ruconest using a production process involving genetically modified rabbits.

Founded in 1988, Pharming serves patients in markets including the United States and Europe, with additional access supported through commercial partners. Its work also includes research and development of medicines for other rare diseases.

View Pharming Group Profile